A Johnson & Johnson building is shown in Irvine, California.
Mike Blake | Reuters
Johnson & Johnson said it expects to begin a late-stage human trial for a potential coronavirus vaccine in late September, ahead of schedule.
The company is in talks with the National Institutes of Health to move up the timeline for the trial, J&J’s Chief Scientific Officer Paul Stoffels said during a post-earnings call Thursday. The company announced earlier in the day that it plans to enter a phase one human trial next week, which will include more than more than 1,000 participants.
J&J is one of several companies working on a potential vaccine for Covid-19, which has infected more than 13 million people worldwide and killed at least 584,000, according to data compiled by Johns Hopkins University.
This is a developing story. Please check back for updates.